Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar; Jesus D. Gonzalez-Lugo; Niyati Goradia; Radhika Gali; Lauren C. Shapiro; Kith Pradhan; Shafia Rahman; So Yeon Kim; Brian Ko; R. Alejandro Sica; Noah Kornblum; Lizamarie Bachier-Rodriguez; Margaret McCort; Sanjay Goel; Roman Perez-Soler; Stuart Packer; Joseph Sparano; Benjamin Gartrell; Della Makower; Yitz D. Goldstein; Lucia Wolgast; Amit Verma; Balazs Halmos

doi:10.1016/j.ccell.2021.06.002

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar
, Jesus D. Gonzalez-Lugo
, Niyati Goradia
, Radhika Gali
, Lauren C. Shapiro
, Kith Pradhan
, Shafia Rahman
, So Yeon Kim
, Brian Ko
, R. Alejandro Sica
, Noah Kornblum
, Lizamarie Bachier-Rodriguez
, Margaret McCort
, Sanjay Goel
, Roman Perez-Soler
, Stuart Packer
, Joseph Sparano
, Benjamin Gartrell
, Della Makower
, Yitz D. Goldstein

Lucia Wolgast, Amit Verma, Balazs Halmos

Research output: Contribution to journal › Article › peer-review

303 Scopus citations

Abstract

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

Original language	English (US)
Pages (from-to)	1081-1090.e2
Journal	Cancer Cell
Volume	39
Issue number	8
DOIs	https://doi.org/10.1016/j.ccell.2021.06.002
State	Published - Aug 9 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
cancer
hematologi malignancies
vaccine

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2021.06.002

Cite this

Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., Kornblum, N., Bachier-Rodriguez, L., McCort, M., Goel, S., Perez-Soler, R., Packer, S., Sparano, J., Gartrell, B., Makower, D., ... Halmos, B. (2021). Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 39(8), 1081-1090.e2. https://doi.org/10.1016/j.ccell.2021.06.002

Thakkar, A, Gonzalez-Lugo, JD, Goradia, N, Gali, R, Shapiro, LC, Pradhan, K, Rahman, S, Kim, SY, Ko, B, Sica, RA , Kornblum, N, Bachier-Rodriguez, L, McCort, M, Goel, S, Perez-Soler, R, Packer, S, Sparano, J, Gartrell, B , Makower, D , Goldstein, YD , Wolgast, L , Verma, A & Halmos, B 2021, 'Seroconversion rates following COVID-19 vaccination among patients with cancer', Cancer Cell, vol. 39, no. 8, pp. 1081-1090.e2. https://doi.org/10.1016/j.ccell.2021.06.002

@article{3065977e79b940ef9e35d38614db6e1e,

title = "Seroconversion rates following COVID-19 vaccination among patients with cancer",

abstract = "As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94\%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98\%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85\%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70\%) and stem cell transplantation (73\%). Patients receiving immune checkpoint inhibitor therapy (97\%) or hormonal therapies (100\%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.",

keywords = "COVID-19, cancer, hematologi malignancies, vaccine",

author = "Astha Thakkar and Gonzalez-Lugo, \{Jesus D.\} and Niyati Goradia and Radhika Gali and Shapiro, \{Lauren C.\} and Kith Pradhan and Shafia Rahman and Kim, \{So Yeon\} and Brian Ko and Sica, \{R. Alejandro\} and Noah Kornblum and Lizamarie Bachier-Rodriguez and Margaret McCort and Sanjay Goel and Roman Perez-Soler and Stuart Packer and Joseph Sparano and Benjamin Gartrell and Della Makower and Goldstein, \{Yitz D.\} and Lucia Wolgast and Amit Verma and Balazs Halmos",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = aug,

day = "9",

doi = "10.1016/j.ccell.2021.06.002",

language = "English (US)",

volume = "39",

pages = "1081--1090.e2",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Seroconversion rates following COVID-19 vaccination among patients with cancer

AU - Thakkar, Astha

AU - Gonzalez-Lugo, Jesus D.

AU - Goradia, Niyati

AU - Gali, Radhika

AU - Shapiro, Lauren C.

AU - Pradhan, Kith

AU - Rahman, Shafia

AU - Kim, So Yeon

AU - Ko, Brian

AU - Sica, R. Alejandro

AU - Kornblum, Noah

AU - Bachier-Rodriguez, Lizamarie

AU - McCort, Margaret

AU - Goel, Sanjay

AU - Perez-Soler, Roman

AU - Packer, Stuart

AU - Sparano, Joseph

AU - Gartrell, Benjamin

AU - Makower, Della

AU - Goldstein, Yitz D.

AU - Wolgast, Lucia

AU - Verma, Amit

AU - Halmos, Balazs

PY - 2021/8/9

Y1 - 2021/8/9

N2 - As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

AB - As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

KW - COVID-19

KW - cancer

KW - hematologi malignancies

KW - vaccine

UR - https://www.scopus.com/pages/publications/85109064956

UR - https://www.scopus.com/pages/publications/85109064956#tab=citedBy

U2 - 10.1016/j.ccell.2021.06.002

DO - 10.1016/j.ccell.2021.06.002

M3 - Article

C2 - 34133951

AN - SCOPUS:85109064956

SN - 1535-6108

VL - 39

SP - 1081-1090.e2

JO - Cancer Cell

JF - Cancer Cell

IS - 8

ER -

Seroconversion rates following COVID-19 vaccination among patients with cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this